Skylar’s shaken when Sasha, the little girl she babysits, is kidnapped. Then Skylar learns she has a hormone in her blood that makes her stronger, faster, smarter—one that the makers of a new drug called Destiny will murder to get. To save Sasha, Skylar must embrace her abilities…and fight Destiny. Find out more at http://www.suzannebrockmann.com/upcoming/night-sky/
Night Sky by Suzanne Brockmann and Melanie Brockmann YA/scifi/fantasy
BMM, Asia’s only Midnight Marathon, was conceived by Rotary Bangalore IT Corridor (RBITC) and the first edition run was held on 19th May 2007. Since then this event is growing from year to year and today people from more than 20 countries are participating in this event and also the number of runners from 2400 in the Year 2007 has increased to 10,000 runners apart from 45 Corporates participating in the event held in 2013, being the seventh edition run. RBITC’s effort in making BMM as a mega event is laudable as it focuses both on bringing about awareness amongst today's youth of the need to be physically fit and mentally strong and also transforming this as a vehicle for raising funds for various charitable activities, aimed at bringing about a difference in the lives of the underprivileged section of the society. To-day BMM has become the largest fund raising platform for RBITC. Some of the major activities undertaken by them are Adoption of Government Schools, Medical Surgeries, Free Eye Surgeries, Holding Blood Donation Camps, Integrated Village Development, Potable Water Project etc.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7398551-bengaluru-midnight-marathon-2014/
Today, WebMD Health Corp. (NASDAQ: WBMD) announced new features and functionality for its Healthy Target behavior change program that connects seamlessly with Apple’s HealthKit and provides users with powerful new ways to capture, visualize and understand health information from a broad range of biometric devices.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70402511-web-md-updates-healthy-target-behavior-change-program-apple-healthkit/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Abbott and the United States Department of Defense today announced a collaboration with the intent to develop portable blood tests to help evaluate potential concussions, also called mild traumatic brain injuries (TBIs). As part of a multi–phased approach, the tests would be developed for Abbott’s i–STAT® System, a handheld, diagnostic analyzer that is currently used for other point-of-care testing, including among military service members. Concussions are a significant health concern for military service members.1 With the development of new tests, physicians could use the information to positively impact the care of people with a suspected concussion.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7293951-abbott-u-s-department-of-defense-develop-portable-blood-tests-concussions/
Stranger in the Dark is based on the story arc of a young girl who moves to a small town.
The horror starts when she wakes up one morning to find herself scared as she confronts her greatest fear, the Stranger in the Dark.
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they’re giving back to their local communities.
Now through March 15, NovoLog® patients can submit their story and photo online for the chance to be crowned a NovoLog® Community Star. Finalists will be selected by a panel of judges, and each will receive a $5,000 donation to a local diabetes-related organization of their choice. One grand prize winner will also receive a one-year online subscription to Weight Watchers® to help with their diabetes management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59947-novo-nordisk-first-novolog-community-star-contest-type-2-diabetes-patients
